The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

View Congress Resources by Therapeutic Area
PLEASE NOTE: Materials will be available on a rolling basis after individual embargoes are lifted. Audio abstracts are generated using text-to-speech software and contain an audio version of the abstract that was submitted and accepted as part of the official conference materials.
Showing 6 of 64 results
Sort by date: Descending
Encores: Not included
Sleep-wake disorders
SLEEP 2026 POSTER
Real-World Experience of Once-Nightly Sodium Oxybate Treatment in People With Narcolepsy: Final Results From REFRESH
AUTHOR(S)

Sarah D. Meskill, MD1; Gerard Meskill, MD1; Asim Roy, MD2; Adrian Santamaria, MD3; Robyn Porpiglio, FNP-C4; Oktai Mamedov, MD5; Sally Ibrahim, MD6,7; Omavi Bailey, MD8; Richard K. Bogan, MD9,10; Laura B. Herpel, MD10,11; Matthew Davis, MD12; Jeremy D. McConnell, MD13; Gretchen S. Richards, MS14; Brian Abaluck, MD14; Jennifer Gudeman, PharmD15,a
 

View poster
Sleep-wake disorders
Sleep-wake disorders
SLEEP 2026 POSTER
REVITALYZ: A Phase 3, Double-Blind, Placebo-Controlled, Randomized, Withdrawal Trial of Extended-Release Sodium Oxybate for Idiopathic Hypersomnia
AUTHOR(S)

Richard K. Bogan, MD, FCCP, FAASM1,2; John Harsh, PhD3; Sally Ibrahim, MD4,5; John C. Carter, MD5,6; Anne Marie Morse, DO7; Bruce C. Corser, MD8; Thomas Stern, MD9; Jacqueline Brooks, MBBCh, MRCPsych10; Brian Abaluck, MD10; Gretchen S. Richards, MS10
 

View poster
Sleep-wake disorders
Sleep-wake disorders
SLEEP 2026 POSTER
Brilliance NT2: Study Design and Methods for a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Alixorexton in Patients With Narcolepsy Type 2
AUTHOR(S)

Richard K. Bogan,1 Emmanuel Mignot,2 Yves Dauvilliers,3 Ronald R. Grunstein,4,5 Gert Jan Lammers,6,7 David T. Plante,8 Rafael del Río Villegas,9,10 Feng Miao,11 Bikram Kabir,11 Juan Chavez,11 Bhaskar Rege,11 Craig Hopkinson,11 Julie Himes,11 Giuseppe Plazzi12,13 

View poster
Sleep-wake disorders
Sleep-wake disorders
SLEEP 2026 POSTER
Demographic and Clinical Characteristics of People Receiving Once-Nightly Sodium Oxybate Treatment: A Specialty Pharmacy Data Analysis
AUTHOR(S)

Chad M. Ruoff, MD1; Michael J. Thorpy, MD2; Laura B. Herpel, MD3,4; Sarah Meskill, MD5; Michelle Vu, PharmD, MPH6; Erin Buysman, MS6; Diana Carino, PharmD, CSP, AAHIVP7; Brian Abaluck, MD8; Jennifer Gudeman, PharmD9,a
 

View poster
Sleep-wake disorders
Sleep-wake disorders
SLEEP 2026 POSTER
Risk Evaluation and Mitigation Strategies: From Burden to Benefit
AUTHOR(S)

Lindsay M. McCullough, MD1; Craig Chepke, MD2; Richard K. Bogan, MD3,4; Martha Curtin, MSPA, PA-C5; Diana Anderson, DMS, PA-C6; Jennifer Gudeman, PharmD7,a; Marla Scarola, MS6; Tracy Gentile, BA8; Danielle Burroughs, RPh6
 

View poster
Sleep-wake disorders
Sleep-wake disorders
ASCP 2026 POSTER
Orexin 2 Receptor Agonists as a Potential Therapeutic Approach to the Treatment of Sleep-Wake Disturbance, Fatigue, and Cognitive Deficit in Neuropsychiatric Disease
AUTHOR(S)

David T. Plante,1 Andrew J. Cutler,2,3 Julie Brooks,4 Ishani Landry,4 Bhaskar Rege,4 Julie Himes,4 Craig Hopkinson,4 and Emmanuel Mignot5

View poster
Sleep-wake disorders